tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Neurocrine initiated with a Buy at Goldman Sachs

Goldman Sachs initiated coverage of Neurocrine (NBIX) with a Buy rating and $182 price target implying 36% upside potential. The firm says Neurocrine has an attractive growth profile relative to its mid-cap peers, given the ongoing Crenessity launch. The company offers significant upside on positive clinical development over the next several years, the analyst tells investors in a research note.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1